{"entity":{"id":"nct05751512","kind":"trial","name":"A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN","aka":[],"tldr":"A phase 3 trial testing MRG003 in head and neck squamous cell carcinoma, now recruiting.","summary":"A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN is a phase 3 interventional study registered as NCT05751512, led by Lepu Biopharma, and recruiting on the registry. Official title: A Randomised, Open-Label, Multicenter, Phase III Study to Evaluate MRG003 vs Cetuximab/Methotrexate as Second/Third Line of Treatment in Patient With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN). Planned enrolment is 180 participants (estimated). The study started in 2023-04-04 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05751512","url":"https://clinicaltrials.gov/study/NCT05751512"}],"tags":["ctgov-ingest"],"related":[],"cancers":["head-and-neck","recurrent-metastatic-hnscc"],"sections":[],"technologies":[],"targets":[],"drugs":["mrg003"],"companies":["lepu-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05751512","phase":"3","setting":"A Randomized, Open-Label, Multicenter, Phase III Study to Evaluate MRG003 vs Cetuximab/Methotrexate as Second/Third Line of Treatment in Patient With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)","sponsor":"Lepu Biopharma","participation":[{"nct":"NCT05751512","source":"https://clinicaltrials.gov/study/NCT05751512","fetchedAt":"2026-10-07T16:53:54.339Z","studySha256":"6633a298a0a4a165de8a80a7995250ae0236795c2d08e5fa5003e8f218be60e5","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-04","leadSponsor":"Lepu Biopharma Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":180,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2023-04-04","startedType":"actual","enrolled":180,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05751512/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/"}],"drug":[{"id":"mrg003","kind":"drug","name":"MRG003","route":"/drugs/mrg003/"}],"company":[{"id":"lepu-biopharma","kind":"company","name":"Lepu Biopharma","route":"/companies/lepu-biopharma/"}]}}